Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 96Recruiting 74Active not recruiting 65Terminated 48Withdrawn 19Unknown 18Not yet recruiting 9Enrolling by invitation 2Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Dermatologic 2Sarcoma 1Lymphoid 1Head & Neck 1Genitourinary 1CNS 1

Conditions

Carcinoma, Renal Cell 1

Interventions

Specimen Handling 5Nivolumab 3Biopsy 3Magnetic Resonance Spectroscopy 2Docetaxel 2talazoparib 1romidepsin 1pembrolizumab 1olaparib 1imisopasem manganese 1gallium 68 PSMA-11 1durvalumab 1balstilimab 1aldesleukin 1abivertinib 1abiraterone 1abarelix 1Watchful Waiting 1Standard of Care 1Radiosurgery 1Practice Guidelines as Topic 1Palliative Care 1Paclitaxel 1Observation 1N-acetylcochinol-O-phosphate 1Mental Status and Dementia Tests 1Menogaril 1Magnetic Resonance Imaging 1Ketones 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × pembrolizumab × Genitourinary × Clear all
NCT06860386 2026-03-06

Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Suspended
75 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡